Month: September 2025

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to demonstrate a tolerable safety profile, consistent with observations from the first 100 patients treated with KYV-1011 Encouraging early data of KYV-101 in multiple sclerosis highlights broader potential within neuroimmunology autoimmune diseases EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced updated data from Phase 1 investigator-initiated trials (IITs) of KYV-101 in the treatment of progressive multiple sclerosis (MS) to be presented at...

VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the “Offering”) of 14,636,363 common shares of the Company (the “Common Shares”), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$5.50 per Common Share for gross proceeds of approximately US$80.5 million, before deducting the underwriting commissions and estimated expenses incurred in connection...

Annual Client Satisfaction Survey Reflects the Views of Senior HR Decision Makers OLD GREENWICH, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) (“Star” or the “Company”), a diversified holding company, announced today that its wholly owned subsidiary, Hudson Talent Solutions (HTS) has ranked among HRO Today magazine’s Baker’s Dozen list of top enterprise recruitment process outsourcing (RPO) providers for the 17th consecutive year. This year, HTS not only maintained its place among the world’s best but also advanced up the rankings, signaling strong momentum in its RPO delivery and client satisfaction. HTS achieved a ranking of #5, in the “Overall Enterprise RPO Leaders” category, which is the highest ranking for HTS over the last 17 years. Of note, HTS ranked #6 in the same category...

Taren Point, Australia, Sept. 24, 2025 (GLOBE NEWSWIRE) — Fitell Corporation (NASDAQ: FTEL) (“FTEL” or the “Company”), today announced its initial acquisition of 46,144 Solana (SOL) for approximately $10 million, marking the first strategic purchase under the Company’s previously announced Solana treasury initiative. “This initial $10 million purchase, in one day following our $100 million financing announcement, manifests FTEL’s execution and commitment to our newly launched Solana treasury strategy” said Sam Lu, Chief Executive Officer of FTEL. “With committed institutional support, we look forward to expanding our SOL position, in addition to growing staking revenue, and drive long-term value for shareholders.” The SOL purchase follows the first closing under the Company’s $100 million facility. FTEL intends to make additional...

Vancouver B.C., Sept. 24, 2025 (GLOBE NEWSWIRE) —  TERRA CLEAN ENERGY CORP. (“Terra” or the “Company”) (CSE: TCEC, OTCQB: TCEFF, FSE: C9O0), is pleased to announce that, further to its press release dated September 16, 2025, it has entered into definitive agreements with arm’s length parties to acquire up to a 100% interest in each of the Wheel Anne Claims and the Green Vein Mesa Claims (each of the properties are located in Emery County, Utah, United States). “The quick execution of the agreements shows the Company’s commitment and excitement to these assets and to our already significant portfolio of low-risk uranium assets in world renowned uranium basins” state Greg Cameron, CEO of Terra. “Our plan is to have our team on the ground in Utah in the coming weeks working closely with our local partner.” To earn its respective...

MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced a strategic partnership with Medcase, a worldwide network of healthcare professionals focused on medical data annotation. This collaboration establishes a new market entry point for OneMedNet and opens a high-growth revenue channel in the healthcare AI ecosystem. Strategic Expansion into Healthcare Data Annotation The global healthcare data annotation market, valued at $1.5 billion in 2025 and projected to be $2.8 billion by 2030, has entered a pivotal growth phase1. Scale AI’s $14.8B investment from Meta has disrupted the industry, triggering an exodus of major clients concerned about competitive intelligence. This shift has created an immediate...

Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be effective in AR-V7 driven tumors BOSTON and LONDON, Sept. 24, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced key preclinical data demonstrating the potential of its novel antibody drug conjugate (ADC) spliceosome modulating payload, PH1, for the treatment of tumors fueled by alternative splicing-drivers, such as the Androgen Receptor splice variant 7 (AR-V7) in prostate cancer. AR-V7 is a key driver for progression of metastatic castration resistant prostate cancer (mCRPC). During progression...

TORONTO, Sept. 24, 2025 (GLOBE NEWSWIRE) — Ultrack Systems Inc. (OTC: MJLB) (“Ultrack” or the “Company”), through its wholly owned subsidiary Better Pets (Better Health Sciences for Pets Corp.), is pleased to announce that it has officially secured a Canadian federal trademark registration for its “Better Pets” brand, while simultaneously advancing its pending U.S. trademark application with the United States Patent and Trademark Office (USPTO). The Canadian trademark (Registration No. TMA1339765, effective August 15, 2025) grants Better Pets the exclusive right to use the ® symbol across Canada for the next ten years, renewable in 2035. This legal protection safeguards the Company’s brand across physical retail, e-commerce, and social platforms while providing a strong foundation for domestic and international expansion. “This...